Rare disease patients in Greater China and Southeast Asia routinely wait years longer than their Western counterparts for therapies that already have regulatory approval elsewhere, and that gap is the specific problem Kos Biotechnology Partners is now funding Golden Age Health to close. Kos, which manages $125 million in assets and counts Greece’s Hellenic Development Bank of Investments among its backers, made the investment through its inaugural Kos BioVentures fund. The size of the stake was not disclosed.
Golden Age Health, founded in 2023 and headquartered in Singapore, operates as a commercial partner for Western and Asian biopharma companies seeking to bring approved or near-approved therapies into Greater China, Southeast Asia, and the Gulf. The company handles regulatory strategy, market access, and real-world evidence generation, taking on the operational complexity that most Western biotechs lack the regional infrastructure to manage themselves. Co-founder Yossi Ben Amram previously ran MSD’s EURAM business, a $4 billion operation spanning more than 100 countries. Co-founder Michel Vounatsos led Biogen as CEO. That combination of commercial-scale and regulatory experience in both Western and Asian markets is what Kos is betting on.
The investment comes with a board seat: Kos co-founder Alex Tzoukas joins the Golden Age Health board, adding a transatlantic biopharma network to a company whose China operations are described as actively scaling. Kos will use its U.S. and European relationships to do something beyond funding GAH’s Asia expansion: it aims to pull high-potential Asian biotech programs back into Western clinical pipelines, making the capital flow genuinely bidirectional. That reverse channel is less common among access-focused platforms, which typically run in one direction.
For trial sponsors and biopharma business development teams, the practical question this raises is whether GAH’s end-to-end model, covering distribution through profit-share and in-licensing arrangements, can compress the lag between Western approval and first patient access in China and APAC. The metric to track is how quickly GAH converts new in-licensing deals into active regulatory filings across its target markets as it deploys this fresh capital.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
